Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genetic variants in immunoregulatory genes and risk for childhood lymphomas.
Andrie E, Michos A, Kalampoki V, Pourtsidis A, Moschovi M, Polychronopoulou S, Athanasiadou-Piperopoulou F, Kalmanti M, Hatzakis A, Paraskevis D, Nieters A, Petridou ET. Andrie E, et al. Among authors: kalampoki v. Eur J Haematol. 2009 Oct;83(4):334-42. doi: 10.1111/j.1600-0609.2009.01288.x. Epub 2009 Jun 5. Eur J Haematol. 2009. PMID: 19508433
Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study.
Feriozzi S, Linhart A, Ramaswami U, Kalampoki V, Gurevich A, Hughes D; Fabry Outcome Survey Study Group. Feriozzi S, et al. Among authors: kalampoki v. Clin Ther. 2020 Dec;42(12):2321-2330.e0. doi: 10.1016/j.clinthera.2020.10.007. Epub 2020 Nov 17. Clin Ther. 2020. PMID: 33218740 Free article.
Analysis of Renal and Cardiac Outcomes in Male Participants in the Fabry Outcome Survey Starting Agalsidase Alfa Enzyme Replacement Therapy Before and After 18 Years of Age.
Parini R, Pintos-Morell G, Hennermann JB, Hsu TR, Karabul N, Kalampoki V, Gurevich A, Ramaswami U; FOS Study Group. Parini R, et al. Among authors: kalampoki v. Drug Des Devel Ther. 2020 Jun 3;14:2149-2158. doi: 10.2147/DDDT.S249433. eCollection 2020. Drug Des Devel Ther. 2020. PMID: 32581513 Free PMC article.
A response to Germain, et al. The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts. Mol Genet Metab Rep Feb 6 2019.
Gurevich A, Schenk J, Wellhoefer H, Kalampoki V. Gurevich A, et al. Among authors: kalampoki v. Mol Genet Metab Rep. 2019 Apr 13;19:100471. doi: 10.1016/j.ymgmr.2019.100471. eCollection 2019 Jun. Mol Genet Metab Rep. 2019. PMID: 31011537 Free PMC article. No abstract available.
30 results